172 related articles for article (PubMed ID: 30643139)
1. Tetrathiomolybdate induces dimerization of the metal-binding domain of ATPase and inhibits platination of the protein.
Fang T; Chen W; Sheng Y; Yuan S; Tang Q; Li G; Huang G; Su J; Zhang X; Zang J; Liu Y
Nat Commun; 2019 Jan; 10(1):186. PubMed ID: 30643139
[TBL] [Abstract][Full Text] [Related]
2. Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1.
Tian Y; Fang T; Yuan S; Zheng Y; Arnesano F; Natile G; Liu Y
Metallomics; 2018 May; 10(5):745-750. PubMed ID: 29721562
[TBL] [Abstract][Full Text] [Related]
3. Ammonium tetrathiomolybdate enhances the antitumor effect of cisplatin via the suppression of ATPase copper transporting beta in head and neck squamous cell carcinoma.
Ryumon S; Okui T; Kunisada Y; Kishimoto K; Shimo T; Hasegawa K; Ibaragi S; Akiyama K; Thu Ha NT; Monsur Hassan NM; Sasaki A
Oncol Rep; 2019 Dec; 42(6):2611-2621. PubMed ID: 31638244
[TBL] [Abstract][Full Text] [Related]
4. Functional interactions of Cu-ATPase ATP7B with cisplatin and the role of ATP7B in the resistance of cells to the drug.
Leonhardt K; Gebhardt R; Mössner J; Lutsenko S; Huster D
J Biol Chem; 2009 Mar; 284(12):7793-802. PubMed ID: 19141620
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of tumor resistance to cisplatin mediated by the copper transporter ATP7B.
Dmitriev OY
Biochem Cell Biol; 2011 Apr; 89(2):138-47. PubMed ID: 21455266
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs.
Lasorsa A; Nardella MI; Rosato A; Mirabelli V; Caliandro R; Caliandro R; Natile G; Arnesano F
J Am Chem Soc; 2019 Jul; 141(30):12109-12120. PubMed ID: 31283225
[TBL] [Abstract][Full Text] [Related]
7. Copper ions are novel therapeutic agents for uterine leiomyosarcoma.
Kakuda M; Matsuzaki S; Ueda Y; Shiomi M; Matsuzaki S; Kimura T; Fujita M; Egawa-Takata T; Kobayashi E; Serada S; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2020 Jan; 222(1):64.e1-64.e16. PubMed ID: 31351063
[TBL] [Abstract][Full Text] [Related]
8. Ammonium tetrathiomolybdate treatment targets the copper transporter ATP7A and enhances sensitivity of breast cancer to cisplatin.
Chisholm CL; Wang H; Wong AH; Vazquez-Ortiz G; Chen W; Xu X; Deng CX
Oncotarget; 2016 Dec; 7(51):84439-84452. PubMed ID: 27806319
[TBL] [Abstract][Full Text] [Related]
9. Human copper transporter ATP7B (Wilson disease protein) forms stable dimers
Jayakanthan S; Braiterman LT; Hasan NM; Unger VM; Lutsenko S
J Biol Chem; 2017 Nov; 292(46):18760-18774. PubMed ID: 28842499
[TBL] [Abstract][Full Text] [Related]
10. Differential Reactivity of Metal Binding Domains of Copper ATPases towards Cisplatin and Colocalization of Copper and Platinum.
Fang T; Tian Y; Yuan S; Sheng Y; Arnesano F; Natile G; Liu Y
Chemistry; 2018 Jun; 24(36):8999-9003. PubMed ID: 29676505
[TBL] [Abstract][Full Text] [Related]
11. Copper chaperone Atox1 interacts with the metal-binding domain of Wilson's disease protein in cisplatin detoxification.
Dolgova NV; Nokhrin S; Yu CH; George GN; Dmitriev OY
Biochem J; 2013 Aug; 454(1):147-56. PubMed ID: 23751120
[TBL] [Abstract][Full Text] [Related]
12. Tetrathiomolybdate inhibits copper trafficking proteins through metal cluster formation.
Alvarez HM; Xue Y; Robinson CD; Canalizo-Hernández MA; Marvin RG; Kelly RA; Mondragón A; Penner-Hahn JE; O'Halloran TV
Science; 2010 Jan; 327(5963):331-4. PubMed ID: 19965379
[TBL] [Abstract][Full Text] [Related]
13. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
Brewer GJ; Merajver SD
Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
[TBL] [Abstract][Full Text] [Related]
14. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm.
Khan G; Merajver S
Expert Opin Investig Drugs; 2009 Apr; 18(4):541-8. PubMed ID: 19335282
[TBL] [Abstract][Full Text] [Related]
15. Copper transporter 1 in human colorectal cancer cell lines: Effects of endogenous and modified expression on oxaliplatin cytotoxicity.
Cui H; Zhang AJ; McKeage MJ; Nott LM; Geraghty D; Guven N; Liu JJ
J Inorg Biochem; 2017 Dec; 177():249-258. PubMed ID: 28551160
[TBL] [Abstract][Full Text] [Related]
16. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu M; Sumizawa T; Mutoh M; Chen ZS; Terada K; Furukawa T; Yang XL; Gao H; Miura N; Sugiyama T; Akiyama S
Cancer Res; 2000 Mar; 60(5):1312-6. PubMed ID: 10728692
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin sensitivity of oral squamous carcinoma cells is regulated by Na+,K+-ATPase activity rather than copper-transporting P-type ATPases, ATP7A and ATP7B.
Ahmed Z; Deyama Y; Yoshimura Y; Suzuki K
Cancer Chemother Pharmacol; 2009 Mar; 63(4):643-50. PubMed ID: 18545997
[TBL] [Abstract][Full Text] [Related]
18. Platination of the copper transporter ATP7A involved in anticancer drug resistance.
Calandrini V; Arnesano F; Galliani A; Nguyen TH; Ippoliti E; Carloni P; Natile G
Dalton Trans; 2014 Aug; 43(31):12085-94. PubMed ID: 24983998
[TBL] [Abstract][Full Text] [Related]
19. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.
Ishida S; McCormick F; Smith-McCune K; Hanahan D
Cancer Cell; 2010 Jun; 17(6):574-83. PubMed ID: 20541702
[TBL] [Abstract][Full Text] [Related]
20. The six metal binding domains in human copper transporter, ATP7B: molecular biophysics and disease-causing mutations.
Ariöz C; Li Y; Wittung-Stafshede P
Biometals; 2017 Dec; 30(6):823-840. PubMed ID: 29063292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
